Source link : https://www.newshealth.biz/health-news/isa-krd-induction-shows-high-mrd-responses/
RIO DE JANEIRO — A quadruplet induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in the treatment of newly diagnosed multiple myeloma (MM) shows a notably high response, with a favorable safety profile, according to the first findings of the ongoing, novel MIDAS trial. “We found that this induction induced exceptionally high response and […]
Author : News Health
Publish date : 2024-10-09 08:32:54
Copyright for syndicated content belongs to the linked Source.
Categories